Group 1 - Changfeng Pharmaceutical Co., Ltd. (stock code: 02652.HK) recently listed on the Hong Kong Stock Exchange, with its stock price opening over 200% higher on the first day and achieving nearly 6700 times oversubscription, setting a record in the healthcare sector since the implementation of the new stock pricing mechanism in Hong Kong [1] - The company focuses on the research, production, and sales of drugs for respiratory diseases, covering significant clinical needs such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis, thus meeting the demands of patients and medical institutions across various specialties [3] - Changfeng Pharmaceutical has received six product approvals from the National Medical Products Administration of China and the U.S. FDA, with its first approved product, CF017 (Budesonide inhalation suspension), being the best-selling inhalation drug in China, rapidly included in the national centralized procurement plan [3] Group 2 - The company’s product CF018 is the first approved nasal spray for allergic rhinitis in China, which has quickly penetrated over 500 hospitals and medical institutions after being included in the 2023 National Medical Insurance Directory [3] - The company has a pipeline of over 20 candidate products under research, targeting major markets in China, the U.S., Europe, and emerging markets in Southeast Asia and South America [3] - Yantai Financial Group has established a comprehensive financial service ecosystem to support high-potential projects, having facilitated 38 companies to enter the capital market and 41 companies into the listing counseling stage [4]
烟台财金集团收获年内第4家IPO企业，长风药业登陆港交所主板